Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Has Average Target Price of $7.50

Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) have been assigned a consensus rating of “Hold” from the seven brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $7.50.

A number of analysts have weighed in on the company. William Blair downgraded Cardiff Oncology from an “outperform” rating to a “market perform” rating in a report on Tuesday, August 11th. Weiss Ratings downgraded Cardiff Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 23rd. HC Wainwright upgraded Cardiff Oncology from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 15th. Finally, Wall Street Zen raised Cardiff Oncology from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 5th.

Institutional Trading of Cardiff Oncology

Several large investors have recently modified their holdings of CRDF. BlackRock Inc. acquired a new position in shares of Cardiff Oncology during the 2nd quarter valued at $1,265,000. GoalVest Advisory LLC acquired a new stake in Cardiff Oncology in the third quarter worth $832,000. Flputnam Investment Management Co. acquired a new stake in Cardiff Oncology in the second quarter worth $322,000. X Square Capital LLC bought a new stake in Cardiff Oncology in the second quarter valued at $267,000. Finally, GSA Capital Partners LLP bought a new stake in Cardiff Oncology in the second quarter valued at $225,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Stock Up 5.3%

Shares of CRDF stock traded up $0.04 during mid-day trading on Friday, reaching $0.80. 345,291 shares of the stock traded hands, compared to its average volume of 416,305. The stock’s fifty day simple moving average is $1.07 and its two-hundred day simple moving average is $1.40. Cardiff Oncology has a 1-year low of $0.75 and a 1-year high of $3.31. The company has a market cap of $61.87 million, a price-to-earnings ratio of -1.33 and a beta of 1.57.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.06 million. On average, equities research analysts anticipate that Cardiff Oncology will post -0.60 EPS for the current fiscal year.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s lead product candidate is onvansertib, an oral, selective inhibitor of polo-like kinase 1 (PLK1), an enzyme involved in cancer-cell division.

Cardiff Oncology has primarily evaluated onvansertib in combination with standard treatments for patients with RAS-mutated metastatic colorectal cancer, including investigations involving KRAS-mutated disease. The company has also explored the candidate in other solid tumors, including metastatic castration-resistant prostate cancer.